21st Austria weekly - Marinomed CA Immo Vienna Airport RBI 14/02/2024 [pic1]Marinomed: Marinomed Biotech AG generated revenues of € 9.2 m in 2023 the majority which was again recognized through sale Carragelose products. As expected revenue decreased by 18.6 % compared to previous year 2022: 11.3 m. This is primarily related lower order volumes following high stock levels partners. Cash and cash equivalents 2.6 8.2 Compared level at end Q3 2023 € 2.8 m this position remained nearly stable as a result stricter management resumption convertible note funding program with Nice & Green. Marinomed’s top priorities 2024 are partnering lead Marinosolv products maximizing value asset well obtaining market approval for US.Marinomed Biotech: